Vise Technologies Inc. lifted its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 66.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 19,503 shares of the medical research company’s stock after buying an additional 7,779 shares during the period. Vise Technologies Inc.’s holdings in Amgen were worth $6,384,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of AMGN. Anfield Capital Management LLC increased its holdings in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares during the period. Dogwood Wealth Management LLC boosted its position in Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares in the last quarter. Board of the Pension Protection Fund bought a new stake in Amgen during the 4th quarter valued at approximately $26,000. Manning & Napier Advisors LLC boosted its position in Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC bought a new stake in shares of Amgen in the 4th quarter worth approximately $33,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.
Amgen Trading Up 1.2%
Shares of Amgen stock opened at $349.58 on Friday. The company has a market capitalization of $188.67 billion, a P/E ratio of 24.33, a P/E/G ratio of 3.47 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The company has a fifty day moving average of $341.35 and a 200 day moving average of $345.47. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29.
Insider Activity at Amgen
In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.85% of the company’s stock.
Amgen News Roundup
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
- Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
- Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title
Analyst Upgrades and Downgrades
AMGN has been the topic of a number of analyst reports. Mizuho boosted their price target on Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. The Goldman Sachs Group set a $389.00 target price on shares of Amgen in a research note on Friday. Royal Bank Of Canada boosted their target price on shares of Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Jefferies Financial Group assumed coverage on Amgen in a research note on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price objective for the company. Finally, Argus reduced their price objective on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, May 20th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Amgen presently has an average rating of “Hold” and an average price target of $353.81.
Get Our Latest Stock Analysis on Amgen
About Amgen
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Read More
- Five stocks we like better than Amgen
- MarketBeat Week in Review – 06/01 – 06/05
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
